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Rationale
• Lung cancer is one of the leading causes of cancer 
related deaths in the United States.
• Although there are other forms of treatment available, 
there is a high demand for less invasive methods.
• Bronchioscopes will deliver appropriate amount of light 
to the tumor site
• Ruthenium complexes have potential to serve as a 
photodynamic therapy agent, however, their safety in a 
mammalian environment needs to be evaluated
• Lung model: Alveolar A549 epithelial cells
• Molecule: Ruthenium complex synthesized at UD by Dr. 
Shawn Swavey
• Safety evaluation: Introduce complex into the culture on 
multiple dosages, incubate for 24 hours, then assess the 
biological response of the cellular system
Figure 1: Experimental Approach
• No cytotoxicity detected after 15 minute exposure to 420 nm light source
• Ruthenium complex was not associating with the A549 cells
• Ruthenium complex has potential as PDT mediator but work needed to 
improve delivery to target tumor site
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Figure 2: 
Ruthenium complex 
structure
Figure 3: Culture cell 
viability in dark following 
complex exposure
Figure 4: Culture cell 
viability following complex 
exposure and irradiation
Figure 5: Complex-
induced stress response 
post irradiation
While the 
complex was able 
to damage DNA, 
no targeted 
destruction 
occurred, likely 
due to low 
cellular delivery.Figure 6: DNA cleavage in 
the (A) presence and (B) 
absence of oxygen following 
irradiation. 
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Figure 7: 
(A) 
Untreated 
and (B) 
complex 
dosed A549 
cells.
